Related Experiment Video
Updated: Feb 8, 2026

Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
Published on: November 22, 2024
FGF21 gene therapy as treatment for obesity and insulin resistance
Veronica Jimenez1,2,3, Claudia Jambrina1,2,3, Estefania Casana1,2,3
1Center of Animal Biotechnology and Gene Therapy (CBATEG), Universitat Autònoma de Barcelona, Bellaterra, Spain.
Abstract:
Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently available therapies are not suited for all patients in the heterogeneous obese/T2D population, hence the need for novel treatments. Fibroblast growth factor 21 (FGF21) is considered a promising therapeutic agent for T2D/obesity. Native FGF21 has, however, poor pharmacokinetic properties, making gene therapy an attractive strategy to achieve sustained circulating levels of this protein. Here, adeno-associated viral vectors (AAV) were used to genetically engineer liver, adipose tissue, or skeletal muscle to secrete FGF21. Treatment of animals under long-term high-fat diet feeding or of ob/ob mice resulted in marked reductions in body weight, adipose tissue hypertrophy and inflammation, hepatic steatosis, inflammation and fibrosis, and insulin resistance for > 1 year. This therapeutic effect was achieved in the absence of side effects despite continuously elevated serum FGF21. Furthermore, FGF21 overproduction in healthy animals fed a standard diet prevented the increase in weight and insulin resistance associated with aging. Our study underscores the potential of FGF21 gene therapy to treat obesity, insulin resistance, and T2D.
Insights
Gene therapy using fibroblast growth factor 21 (FGF21) offers a potential long-term treatment for obesity and type 2 diabetes (T2D). This approach successfully reduced body weight and improved metabolic health in animal models.
Area of Science:
- Metabolic diseases
- Gene therapy
- Endocrinology
Background:
- Rising global prevalence of type 2 diabetes (T2D) and obesity necessitates novel therapeutic strategies.
- Existing treatments for T2D and obesity are not universally effective due to population heterogeneity.
- Fibroblast growth factor 21 (FGF21) shows therapeutic promise, but native forms have poor pharmacokinetics.
Purpose of the Study:
- To evaluate the efficacy of FGF21 gene therapy for treating T2D and obesity.
- To assess the long-term metabolic benefits and safety of sustained FGF21 production.
- To explore FGF21's potential in preventing age-related metabolic decline.
Main Methods:
- Adeno-associated viral vectors (AAV) were employed for FGF21 gene delivery to liver, adipose, or skeletal muscle.
- Animal models, including those on high-fat diets and ob/ob mice, were utilized.
- Metabolic parameters, body weight, and tissue health were monitored over extended periods.
Main Results:
- Sustained FGF21 secretion via gene therapy led to significant reductions in body weight and adipose tissue hypertrophy/inflammation.
- Improvements were observed in hepatic steatosis, inflammation, fibrosis, and insulin resistance lasting over a year.
- FGF21 gene therapy prevented weight gain and insulin resistance in healthy animals during aging, with no observed side effects.
Conclusions:
- FGF21 gene therapy represents a promising strategy for durable treatment of obesity and T2D.
- This approach effectively addresses multiple facets of metabolic dysfunction.
- Gene therapy offers a viable alternative to overcome the pharmacokinetic limitations of native FGF21.
Related Concept Videos
Gene Therapy
Treatment Resistant Cancers
Obesity
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Insulin Secretory Vesicles
Resistivity

